Cautious Optimism For Capital Markets
Life sciences capital markets in 2025 have been a mixed bag—some rays of light peeking through, but still, plenty of clouds for early-stage companies hoping to tap the public markets. After a long IPO drought, 2024 brought a few green shoots, with several life sciences companies testing the waters. The modest increases in 2024, as seen in a handful of IPOs—mostly by companies with later-stage assets, strong data, or a well-known management team—signaled continued momentum into 2025....By: Ballard Spahr LLP
Read More